735472.fig.003a
(a)
735472.fig.003b
(b)
735472.fig.003c
(c)
735472.fig.003d
(d)
735472.fig.003e
(e)
735472.fig.003f
(f)
Figure 3: In vivo inflammatory response of equine metacarpal-phalangeal joints treated by the intra-articular administration of adenoviral (Ad), recombinant adeno-associated viral (rAAV2), or self-complementary AAV (scAAV2) vectors carrying green fluorescent protein (GFP) genes. (a) Joint fluid protein concentration, (b) joint fluid white blood cell count, (c) % changes of joint circumference, (d) % changes of the range of joint motion, (e) joint fluid interleukin-1-beta concentration of the Ad-, rAAV2-, or scAAV2-injected joints, and (f) lameness grade. *Significantly greater than all other groups ( ). The Ad-injected joints showed significantly greater inflammatory responses compared to the rAAV2/scAAV2-injected joints, although all parameters were returned within normal range in 4-5 weeks after the joint injection.